Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (41-50 of 331) with videos related to

Pageof 34
Sort By:
American Journal of Clinical Dermatology|June 23, 2022
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic ReviewMette Gyldenløve, Farzad Alinaghi, Claus Zachariae, et al.
Chemistryopen|December 28, 2020
Pyridine-based Liquid-Phase Synthesis of Crystalline TiN and ZnSiN<sub>2</sub> NanoparticlesAlexander Egeberg, Olivia Wenzel, Radian Popescu, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Adverse Events in Patients Receiving Placebo in Phase III Trials of Biologics for Psoriasis: A Systematic Review and Meta-AnalysisGayathri Devaraj Ajenthen, Alexander Egeberg, Katrine Elsner Melgaard, et al.
Cutis|March 21, 2017
The role of biologic therapy for psoriasis in cardiovascular risk reductionDaniel J No, Mina Amin, Alexander Egeberg, et al.
The Journal of Dermatological Treatment|May 8, 2018
Drug survival of secukinumab for psoriasis in a real-world settingErica B Lee, Mina Amin, Alexander Egeberg, et al.
Chemical Communications (Cambridge, England)|August 18, 2018
Pyridine-based low-temperature synthesis of CoN, Ni<sub>3</sub>N and Cu<sub>3</sub>N nanoparticlesAlexander Egeberg, Lucas Warmuth, Sven Riegsinger, et al.
Acta Dermato-Venereologica|May 4, 2016
Prognosis after Hospitalization for ErythrodermaAlexander Egeberg, Jacob P Thyssen, Gunnar H Gislason, et al.
The American Journal of Cardiology|July 4, 2016
Relation of Periodontitis to Risk of Cardiovascular and All-Cause Mortality (from a Danish Nationwide Cohort Study)Gorm Mørk Hansen, Alexander Egeberg, Palle Holmstrup, et al.
American Journal of Clinical Dermatology|October 29, 2017
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Mina Amin, Daniel J No, Alexander Egeberg, et al.
The Journal of Investigative Dermatology|August 22, 2018
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort StudyAlexander Egeberg, Jacob P Thyssen, Johan Burisch, et al.
Pageof 34

Showing results (41-50 of 331) with videos related to

Sort By:
Pageof 34
American Journal of Clinical Dermatology|June 23, 2022
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic ReviewMette Gyldenløve, Farzad Alinaghi, Claus Zachariae, et al.
Chemistryopen|December 28, 2020
Pyridine-based Liquid-Phase Synthesis of Crystalline TiN and ZnSiN<sub>2</sub> NanoparticlesAlexander Egeberg, Olivia Wenzel, Radian Popescu, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Adverse Events in Patients Receiving Placebo in Phase III Trials of Biologics for Psoriasis: A Systematic Review and Meta-AnalysisGayathri Devaraj Ajenthen, Alexander Egeberg, Katrine Elsner Melgaard, et al.
Cutis|March 21, 2017
The role of biologic therapy for psoriasis in cardiovascular risk reductionDaniel J No, Mina Amin, Alexander Egeberg, et al.
The Journal of Dermatological Treatment|May 8, 2018
Drug survival of secukinumab for psoriasis in a real-world settingErica B Lee, Mina Amin, Alexander Egeberg, et al.
Chemical Communications (Cambridge, England)|August 18, 2018
Pyridine-based low-temperature synthesis of CoN, Ni<sub>3</sub>N and Cu<sub>3</sub>N nanoparticlesAlexander Egeberg, Lucas Warmuth, Sven Riegsinger, et al.
Acta Dermato-Venereologica|May 4, 2016
Prognosis after Hospitalization for ErythrodermaAlexander Egeberg, Jacob P Thyssen, Gunnar H Gislason, et al.
The American Journal of Cardiology|July 4, 2016
Relation of Periodontitis to Risk of Cardiovascular and All-Cause Mortality (from a Danish Nationwide Cohort Study)Gorm Mørk Hansen, Alexander Egeberg, Palle Holmstrup, et al.
American Journal of Clinical Dermatology|October 29, 2017
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Mina Amin, Daniel J No, Alexander Egeberg, et al.
The Journal of Investigative Dermatology|August 22, 2018
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort StudyAlexander Egeberg, Jacob P Thyssen, Johan Burisch, et al.
Pageof 34